NRx Pharmaceuticals Plans Underwritten Public Offering
NRx Pharmaceuticals announced that it intends to offer shares of its common stock in an underwritten public offering. The company currently intends to use the net proceeds from the offering for working capital and general corporate purposes to support its growth. BTIG is acting as the lead bookrunner for the offering. Lucid Capital Markets is acting as joint bookrunning manager for the offering.
